VAG
CKPT

VisionPoint Advisory Group’s Checkpoint Therapeutics CKPT Stock Holding History

VisionPoint Advisory Group’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$215 – 336
2024
Q2 		$215 Hold
100
– – ﹤0.01% 760
2024
Q1 		$205 Buy
+100
New +$199 ﹤0.01% 766

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VisionPoint Advisory Group's CKPT Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of Checkpoint Therapeutics (CKPT) in Q3 2024, closing a stake of 100 shares — an estimated $215 sold.

VisionPoint Advisory Group first reported a position in CKPT in Q1 2024 and held it in 2 quarters. The position peaked at $215 in Q2 2024. 47 funds tracked by Wall St. Rank hold CKPT as of Q3 2024.

  • VisionPoint Advisory Group reported no remaining Checkpoint Therapeutics position as of Q3 2024 after selling out during the quarter.
  • VisionPoint Advisory Group sold 100 Checkpoint Therapeutics shares in Q3 2024, an estimated $215.
  • VisionPoint Advisory Group first reported a position in Checkpoint Therapeutics in Q1 2024 and held it in 2 quarters.
  • VisionPoint Advisory Group's Checkpoint Therapeutics position peaked at $215 in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.